Chimerix to Announce Fourth Quarter and Full Year 2017 Financial Results on March 1, 2018

DURHAM, N.C., Feb. 22, 2018 (GLOBE NEWSWIRE) -- Chimerix, Inc. (Nasdaq:CMRX), a biopharmaceutical company developing novel antivirals for the growing population of immunocompromised patients, today announced that it will host a live conference call and audio webcast on Thursday, March 1, 2018 at 8:30 a.m. ET to report financial results for the fourth quarter and full year ended December 31, 2017, and to provide a business overview.

To access the live conference call, please dial (877) 354-4056 (domestic) or (678) 809-1043 (international) at least five minutes prior to the start time, and refer to conference ID 1153769. A live audio webcast of the call will also be available on the Investors’ section of the Company's website, www.chimerix.com. An archived webcast will be available on the Chimerix website approximately two hours after the event.

About Chimerix

Chimerix is a biopharmaceutical company dedicated to discovering, developing and commercializing medicines that improve outcomes for immunocompromised patients. Chimerix's proprietary lipid conjugate technology and Compound Library have produced brincidofovir (BCV, CMX001); CMX157, which was licensed to ContraVir Pharmaceuticals; and a new clinical candidate, CMX521, the first direct-acting antiviral specifically for the treatment and prevention of norovirus to enter clinical testing. For further information, please visit Chimerix's website, www.chimerix.com.

CONTACT:

Investor Relations:
Michelle LaSpaluto
919-972-7115
ir@chimerix.com
or
Will O’Connor
Stern Investor Relations
Will@sternir.com
212-362-1200

Media:

Becky Vonsiatsky
W2O Group
bvonsiatsky@w2ogroup.com
413-478-2003

Source:Chimerix, Inc.